NCT04323956 2026-02-02
Parsaclisib Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma
Mayo Clinic
Phase 1 Active not recruiting
Mayo Clinic
Medical College of Wisconsin
National Cancer Institute (NCI)
Sun Yat-sen University
University of Virginia